Bristol Myers Squibb stock may trade 48% below fair value on AI drug discovery push

Bristol-Myers Squibb has benefited from a 42.2% stock return over the past year, driven by growing market optimism around the company's strategic moves. The catalyst for renewed attention is the company's expanded collaboration with Nvidia on AI systems and the opening of a new San Diego R&D hub, both aimed at strengthening long-term cash flow generation.

A Discounted Cash Flow valuation analysis suggests the stock may be trading well below its intrinsic value. The model uses the company's latest twelve month free cash flow of about $12b as its foundation and projects future cash flows that gently decline before settling into a steady pattern. On this basis, the estimated intrinsic value comes to about $123 per share. Compared with the current share price, this implies Bristol-Myers Squibb trades at roughly a 48.1% discount to that intrinsic value, suggesting the stock appears undervalued on a cash flow basis.

The valuation picture, however, is not entirely straightforward. The company scores 4 out of 6 on overall valuation checks, pointing to a mixed assessment rather than a clear bargain or clear overvaluation. The key question for investors is whether the current price already reflects the intrinsic value suggested by the DCF estimate — in which case the apparent discount may be illusory — or whether it still leaves a meaningful margin of safety. Regulatory uncertainty around partnered drugs and broader pipeline outcomes remain potential headwinds that could dampen the durability of the projected cash flows underlying the valuation model.

Bristol-Myers Squibb's stock has attracted fresh attention following the company's expanded AI work with Nvidia and the establishment of a new San Diego R&D hub. These moves appear to have bolstered investor confidence, reflected in the 42.2% one-year return. However, the valuation picture remains mixed: a Discounted Cash Flow analysis points to meaningful undervaluation (48.1% discount to estimated intrinsic value), while the overall valuation checklist scores 4 out of 6, suggesting neither a clear bargain nor obvious overvaluation.

The DCF model underpinning the undervaluation thesis uses a latest twelve month free cash flow of about $12b as its starting point and assumes cash flows that decline before settling into a steady pattern, arriving at an intrinsic value of about $123 per share. The gap between this estimate and the current market price suggests potential upside — but only if the assumptions hold and the market has not already priced in the AI and R&D hub benefits. Regulatory uncertainty around partnered drugs and broader pipeline outcomes present a key risk to the durability of projected cash flows, meaning the 48.1% discount may not translate to realized returns if those headwinds materialize.

No comments yet. Be the first to share your thoughts!